
Stafib-2
CAS No. 2097938-74-2
Stafib-2( Stafib 2 )
Catalog No. M13314 CAS No. 2097938-74-2
Stafib-2 (Stafib 2)?is a potent, selective small molecule inhibitor of transcription factor STAT5b with Ki of 9 nM, >20-fold selectivity over STAT5a.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 596 | Get Quote |
![]() ![]() |
10MG | 848 | Get Quote |
![]() ![]() |
25MG | 1251 | Get Quote |
![]() ![]() |
50MG | 1692 | Get Quote |
![]() ![]() |
100MG | 2304 | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameStafib-2
-
NoteResearch use only, not for human use.
-
Brief DescriptionStafib-2 (Stafib 2)?is a potent, selective small molecule inhibitor of transcription factor STAT5b with Ki of 9 nM, >20-fold selectivity over STAT5a.
-
DescriptionStafib-2 (Stafib 2)?is a potent, selective small molecule inhibitor of transcription factor STAT5b with Ki of 9 nM, >20-fold selectivity over STAT5a.
-
In VitroStafib-2 has an extremely high affinity for STAT5b (Ki=8.8 nM).Stafib-2 (3-10 μM; 4-48 h) does not show significant activity in K562 and MDA-MB-231 cells.
-
In Vivo——
-
SynonymsStafib 2
-
PathwayJAK/STAT Signaling
-
TargetSTAT
-
RecptorSTAT
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2097938-74-2
-
Formula Weight644.466
-
Molecular FormulaC28H26N2O12P2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (77.58 mM)
-
SMILES——
-
Chemical Name4-((2-(4-((4-phenoxyphenyl)carbamoyl)phenoxy)acetamido)methyl)-1,2-phenylene bis(dihydrogen phosphate)
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference



-
NT219
NT219 is a dual inhibitor of insulin receptor substrate 1/2 (IRS1/2) and STAT3, enhances the aggregation of misfolded prion protein NT219 affects the levels of certain molecular chaperones and inhibits STAT3 phosphorylation NT219 is useful for the study of cancer and neurodegenerative diseases.
-
Palivizumab
Palivizumab (MEDI 493) is a humanized RSV-specific monoclonal antibody that selectively inhibits epitopes at the F protein A antigenic site of RSV subtypes A and B for the prevention of respiratory syncytial virus infection (RSV).
-
CAY10784
CAY10784 (STAT3-IN-17) is a STAT3 inhibitor with antiproliferative and antitumor activities. CAY10784 showed antibacterial activity against Clostridium difficile.